Skip to main content
introducing-new-mechanism-drugs-protect-the-road-to-transplant-rebirth-meiji-pharmaceutical-and-patientsforce-to-reduce-the-medication-burden-of-cgvhd-patients-copy
2026-04-07

2026 Next Steps for Taiwan’s Patient Support Program

By Nerrisa Kuo, Director of PatientsForce

From service execution to value-outcome-driven healthcare platforms

The Patient Support Program (PSP) market has grown rapidly in Taiwan over the past few years. But if we look back from 2026, we see that the very nature of PSPs has fundamentally changed. It is no longer just a “patient care service”, nor is it just a medication reminder, health education tracking, or customer service mechanism, but a key watershed moment in the era of value-based care .

The core of the truly competitive PSP of the future is not how many services it provides, but about:

whether it can substantially improve patient outcomes, enhance medical efficiency, and create quantifiable value for the healthcare system.

The PSP is being redefined

From the perspective of the development of the global pharmaceutical industry, PSP has gradually upgraded from a support function to a core component of pharma strategy.

Especially in the fields of oncology, rare disease, autoimmune diseases, and specialty care, PSP has directly impacted:

  • The patient initiates the treatment velocity
  • Treatment Persistence
  • Interruption rate and churn rate
  • Clinical outcome tracking
  • Patient Quality of Life (QoL)

In the past, pharmaceutical companies evaluated PSPs and focused on service volume, such as the number of calls, contact frequency, and satisfaction. But now the market cares more about:

Whether PSP really improves treatment outcomes.For example:

  • Whether the 3-month continuous medication use rate has increased
  • Whether the return visit rate has improved
  • Whether hospitalizations and emergency departments have declined
  • Whether adverse events (dverse events) were detected earlier

This shift from process KPIs to outcome KPIs will completely rewrite the design thinking of PSPs.

AI will be the biggest booster for PSP upgrades

Another key trend in 2026 is the rapid entry of AI into patient support processes. The role of AI in PSP is not to replace people, but to redistribute the value of professional manpower. For example:

Low-risk, standardized questions that can be completed with the help of AI:

  • Symptoms are initially triaged
  • Medication reminder
  • Return appointments
  • FAQ Health education
  • Emotional risk warning

For high-risk patients, complex treatments, and psychological support, professional nurses and personal management teams are deeply involved. This is not just an efficiency improvement, but also a care model redesign. In the face of the ongoing shortage of medical manpower, this will become the most important capability in the next three years.

The next phase of PSP in Taiwan is not just in the hospital, but in the patient’s home

Taiwan has a highly accessible health insurance system, but it also faces an aging population, the burden of chronic diseases, and medical manpower pressure. The most important development direction for PSP in the future is to move from hospital-based support to home-based continuous care.

Especially in the field of cancer and special drugs, the real challenges faced by patients are often not in the clinic room, but after returning home. Includes:

  • Side effect management
  • Treatment adherence
  • Family care pressure
  • Mood Anxiety Support
  • Remote monitoring of physiological data

This is also an important direction that PatientsForce has continued to invest in in recent years: to extend patient support from the hospital to life scenarios.

The PSP will be the key to real-world evidence

The value of the future PSP is by no means just about service.

More importantly, it will become a platform for generating Real-World Data (RWD) and Real-World Evidence (RWE). Through authentic interactions in the patient journey, sustainable accumulation:

  • Medication continuity rate
  • Adverse reaction patterns
  • symptom burden
  • patient-reported outcomes
  • quality of life indicators

This data is not only valuable for healthcare but also supports:

  • HTA
  • reimbursement negotiation
  • HEOR
  • market access strategy
  • lifecycle evidence generation

Who can prove with data that they are truly improving patient outcomes.This includes:

  • Higher treatment continuity rates
  • Lower hospitalization rates
  • Better patient experience
  • Better health economic outcomes

The future PSP is more than just an extension of medical services. It will be the most important value platform connecting patients, pharmaceutical companies, medical institutions and digital technology. And this is also the most anticipated transformation direction of Taiwan’s medical industry in the next stage.

Source of the source

  • IQVIA (2026).，Four Forces Reshaping Patient Support in 2026.
  • Deloitte (2026). The 2026 Global Health Care Outlook.
  • WTW (2026). Global Medical Trends Survey Report – Asia Pacific Insights.
  • Taiwan’s Ministry of Health and Welfare (2025), announced the revision of the “National Health Insurance Home Emergency Care Pilot Plan”
  • National Science and Technology Council (2025), “Vision and Action for Home Medical Technology”

Article Search

Latest articles